Stryker Corporation $SYK Shares Sold by Evelyn Partners Investment Management Services Ltd

Evelyn Partners Investment Management Services Ltd reduced its position in shares of Stryker Corporation (NYSE:SYK) by 50.7% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 95,005 shares of the medical technology company’s stock after selling 97,894 shares during the quarter. Stryker comprises 3.6% of Evelyn Partners Investment Management Services Ltd’s portfolio, making the stock its 7th largest holding. Evelyn Partners Investment Management Services Ltd’s holdings in Stryker were worth $35,892,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in SYK. Nuveen LLC purchased a new position in shares of Stryker during the first quarter valued at $558,075,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Stryker by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after purchasing an additional 1,021,496 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of Stryker by 66.7% in the first quarter. Alliancebernstein L.P. now owns 1,373,142 shares of the medical technology company’s stock worth $511,152,000 after purchasing an additional 549,643 shares during the period. ABN AMRO Bank N.V. bought a new position in shares of Stryker during the 2nd quarter worth approximately $191,047,000. Finally, Vanguard Group Inc. raised its stake in shares of Stryker by 1.3% in the second quarter. Vanguard Group Inc. now owns 33,500,571 shares of the medical technology company’s stock valued at $13,253,831,000 after acquiring an additional 440,607 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Up 2.2%

Shares of Stryker stock opened at $368.35 on Friday. The company has a market cap of $140.87 billion, a price-to-earnings ratio of 48.79, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The company’s 50 day moving average is $369.38 and its 200 day moving average is $380.68. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same quarter in the previous year, the firm posted $2.87 EPS. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Insider Activity

In related news, CAO William E. Berry, Jr. sold 1,953 shares of the firm’s stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the transaction, the chief accounting officer owned 2,833 shares of the company’s stock, valued at $1,035,433.17. This trade represents a 40.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Viju Menon sold 500 shares of the business’s stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 522,618 shares of company stock worth $185,577,237 in the last ninety days. 5.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have recently commented on SYK. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Royal Bank Of Canada reissued an “outperform” rating and issued a $435.00 target price on shares of Stryker in a research report on Friday, November 14th. Barclays raised their price target on shares of Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Rothschild Redb raised shares of Stryker to a “hold” rating in a research note on Thursday, September 18th. Finally, Rothschild & Co Redburn initiated coverage on shares of Stryker in a research note on Thursday, September 18th. They set a “neutral” rating and a $420.00 price target on the stock. Thirteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and a consensus target price of $434.37.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.